Chlamydia species cause a broad spectrum of diseases in humans including severe chronic sequelae related to persistent forms. Despite the lack of detectable amounts of peptidoglycan, several studies suggest the presence of small quantities of peptidoglycan or its derivative at least in some stages of the growth cycle. Based on recent discovery in Chlamydiae of the aminotransferase pathway for biosynthesis of meso-diaminopimelic acid, we demonstrated the up-regulation of the gene (cp0259) encoding L,L-diaminopimelate aminotransferase in chlamydial persistent forms. This finding may be important in the search for target molecules to diagnose and treat Chlamydia-associated chronic diseases.
WyrickPB. Chlamydia trachomatis persistence in vitro: An overview. J Infect Dis2010; 201:S88–95.
2.
DlugoszAZakikhanyKMuschiolSHultenbyKLindbergG., Infection of human enteroendocrine cells with Chlamydia trachomatis: A possible model for pathogenesis in irritable bowel syndrome. Neurogastroenterol Motil2011; 23(10):928–34.
3.
SessaRDi PietroMSantinoIdel PianoMVarveriADagiantiAPencoM. Chlamydia pneumoniae infection and atherosclerotic coronary disease. Am Heart J1999; 137(6): 1116–9.
4.
SessaRDi PietroMSchiavoniGSantinoICiprianiPRomanoSPencoMdel PianoM. Prevalence of Chlamydia pneumoniae in peripheral blood mononuclear cells in Italian patients with acute ischaemic heart disease. Atherosclerosis2001; 159(2):521–5.
5.
SessaRDi PietroMSchiavoniGSantinoIBenedetti-ValentiniFPernaRRomanoSdel PianoM. Chlamydia pneumoniae DNA in patients with symptomatic carotid atherosclerotic disease. J Vasc Surg2003; 37(5): 1027–31.
6.
RomanoSFratiniSDi PietroM. Chlamydia pneumoniae infection in patients with acute coronary syndrome: A clinical and serological 1-year follow-up. Int J Immunopathol Pharmacol2004; 17(2):209–18.
7.
RomanoSPencoMFratiniSDi PietroMSessaRDel PianoMFedeleFDagiantiA. Chlamydia pneumoniae infection is associated with coronary artery disease but not implicated in inducing plaque instability. Int J Cardiol2004; 95(1):95–9.
8.
SessaRDi PietroMSchiavoniG. Detection of Chlamydia pneumoniae in atherosclerotic coronary arteries. Int J Immunopathol Pharmacol2004; 17:301–306.
9.
SessaRSchiavoniGDi PietroM. Chlamydia pneumoniae in PBMC: Reproducibility of the ompA nested touchdown PCR. Int J Immunopathol Pharmacol2005; 18:113–120.
10.
SessaR.Di PietroMSchiavoniG., Chlamydia pneumoniae in asymptomatic carotid atherosclerosis. Int J Immunopathol Pharmacol2006; 19:111–8.
11.
SessaRDi PietroMSchiavoniGPetruccaACiprianiPZagagliaCNicolcttiMSantinoIdel PianoM. Measurement of Chlamydia pneumoniae bacterial load in peripheral blood mononuclear cells may be helpful to assess the state of chlamydial infection in patients with carotid atherosclerotic disease. Atherosclerosis2007; 195(1):e224–30.
12.
SessaRCiprianiPDi PietroMSchiavoniGSantinoIdel PianoM. Chlamydia pneumoniae and chronic diseases with a great impact on public health. Int J Immunopathol Pharmacol2008; 21(4): 1041–3.
13.
Di PietroMSchiavoniGdel PianoM. Chlamydia pneumoniae and atherosclerosis: The role of mast cells. J Biol Regul Homeost Agents2009; 23(2):65–9.
14.
SessaRNicolettiMDi PietroMSchiavoniGSantinoIZagagliaCdel PianoMCiprianiP. Chlamydia pneumoniae and atherosclerosis: Current state and future prospectives. Int J Immunopathol Pharmacol2009; 22(1):9–14.
15.
SessaRDi PietroMSchiavoniG. Chlamydia pneumoniae induces T cell apoptosis through glutathione redox imbalance and secretion of TNF-alpha. Int J Immunopathol Pharmacol2009; 22(3):659–68.
16.
SchiavoniGDi PietroMRoncoC. Chlamydia pneumoniae infection as a risk factor for accelerated atherosclerosis in hemodialysis patients. J Biol Regul Homeost Agents2010; 24(3):367–75.
17.
Di PietroMSchiavoniGSessaVPallottaFCostanzoGSessaR. Chlamydia pneumoniae and osteoporosis associated bone loss: A new risk factor?Osteoporos Int2012. In press (DOI 10.1007/s00198-012-2217-1).
18.
CollinaFDe ChiaraADe RenzoADe RosaGBottiGFrancoR. Chlamydia psittaci in ocular adnexa MALT lymphoma: A possible role in lymphomagenesis and a different geographical distribution. Infect Agent Cancer2012; 7:8.
19.
McCoyAJMaurelliAT. Building the invisible wall: Updating the chlamydial peptidoglycan anomaly. Trends Microbiol2006; 14(2):70–7.
20.
PavelkaMSJr. Another brick in the wall. Trends Microbiol2007; 15(4): 147–9.
21.
GhuysenJMGoffinC. Lack of cell wall peptidoglycan versus penicillin sensitivity: New insights into the chlamydial anomaly. Antimicrob Agents Chemother1999; 43(10):2339–44.
22.
BrownWJRockeyDD. Identification of an antigen localized to an apparent septum within dividing chlamydiae. Infect Immun2000; 68(2):708–15.
Welter-StahlLOjciusDMVialaJ. Stimulation of the cytosolic receptor for peptidoglycan, Nodi, by infection with Chlamydia trachomatis or Chlamydia muridarum. Cell Microbiol2006; 8(6): 1047–57.
25.
McCoyAJAdamsNEHudsonAOGilvargCLeustekTMaurelliAT. L,L-diaminopimelate aminotransferase, a trans-kingdom enzyme shared by Chlamydia and plants for synthesis of diaminopimelate/lysine. Proc Natl Acad Sci USA2006; 103(47): 17909–14.
26.
WatanabeNClayMDvan BelkumMJFanCVederasJCJamesMN. The structure of LL-diaminopimelate aminotransferase from Chlamydia trachomatis: Implications for its broad substrate specificity. J Mol Biol2011; 411(3):649–60.
27.
Di PietroMTramontiADe SantisFDe BiaseDSchiavoniGFilardoSZagagliaCSessaR. Analysis of gene expression in penicillin G induced persistence of Chlamydia pneumoniae. J Biol Regul Homeost Agents2012; 26(2):277–84.
28.
MaurerAPMehlitzAMollenkopfHJMeyerTF. Gene expression profiles of Chlamydophila pneumoniae during the developmental cycle and iron depletion-mediated persistence. PLoS Pathog2007; 3(6):e83.
29.
BellandRJNelsonDEVirokDCraneDDHoganDSturdevantDBeattyWLCaldwellHD. Transcriptome analysis of chlamydial growth during IFN-gamma-mediated persistence and reactivation. Proc Natl Acad Sci US A2003; 100(26): 15971–6.
